🇺🇸 FDA
Pipeline program

Part A: Dose Escalation of Cantrixil

NVGN-002-101

Phase 1 small_molecule completed

Quick answer

Part A: Dose Escalation of Cantrixil for Ovarian Neoplasms is a Phase 1 program (small_molecule) at KAZIA THERAPEUTICS LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
KAZIA THERAPEUTICS LTD
Indication
Ovarian Neoplasms
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials